Back to News
Market Impact: 0.3
Caris Q3 Profit Falls On Higher Expenses; Raises FY26 Revenue Guidance After 27% Revenue Growth
Source: Nasdaq
Corporate EarningsCorporate Guidance & OutlookHealthcare & BiotechCompany Fundamentals
Caris Life Sciences reported 27% revenue growth in the third quarter and raised its full-year revenue guidance. Net income declined as expenses increased, tempering the positive revenue and outlook news.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
CAI0.35
More News
- TD Cowen raises Caris Life Sciences stock price target on pipeline
- Tech stocks are suffering their biggest selloff since Covid, as investors see premature end to AI datacenter boom
- Elon Musk's Tesla and SpaceX lose over $420 billion in combined market cap after midterms
- We're raising our price target on Cardinal Health after another stellar quarter of profits
- Costco is taking aim at its May record high — how it got here and where's it going
- Neocloud IREN says $4 billion in annualized revenue being delayed due to customer request